A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

HealthWorksAI Unveils the First Healthcare Data Platform Using xAI Technology

HealthWorksAI, an industry-leading Healthcare analytics company, announces the launch of the 2nd generation of their state-of-the-art xAI program. It’s an advanced analytical approach that collects and processes data, generating in-depth market analysis which standard models do not uncover.

Allowing data scientists an efficient way to measure the impact of various plan attributes/factors, xAI provides a better understanding of the correlation between plan features and beneficiary preference. It also provides insights into the influence of multiple verticals at the market level. The models are then combined with the human-computer interface (HCI) features capable of translating models into practical explanations for end users.

We use a combination of Rule-based algorithms, Random Forest, and Artificial Neural Networks to develop our proprietary prediction, classification, and performance metrics,” says Shreya, Data Scientist of HealthWorksAI™. “Advanced analytics & xAI comes to play in the modeling and evaluation phases of data mining. To achieve this, we use LIME and DeepLIFT, as an example, to achieve far superior results.”

The xAI program, released in early 2021, has been a huge success for HealthWorksAI, leading as their most subscribed platform module in its first year. The 2nd generation, which will see releases begin in early Q2, includes multiple platform enhancements as well as new approaches to xAI methodologies.

“We’re excited to announce the expansion of our xAI program for MA Payors,” noted Jereme Ayers, Chief Growth Officer of HealthWorksAI. “One of the defining aspects of our company is the partnership our clients provide. We appreciate their faith and confidence and look forward to delivering even more for them in 2022!”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy